Through this license agreement, SIRION Biotech GmbH granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.
Allogeneic CAR-T cell therapy represents a future-defining shift in simplicity, availability, and cost-efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient-derived cells, elevates the technology to the level of a realistic off-the-shelf product.
Dr Christian Thirion, CEO and founder of SIRION explains: “LentiBOOST™ improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells.”
“We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs,” says SVP BD & Licensing Dr Sabine Ott.
For more information, please fill out the enquiry form attached to this page.